Insulin Glargine Safety in Pregnancy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence of hypoglycemia provide potential advantages for its use in pregnancy. However, the placental pharmacokinetics of insulin glargine have not been studied. Therefore, the objective of this study was to determine whether insulin glargine crosses the human placenta using the human perfused placental lobule technique. RESEARCH DESIGN AND METHODS: Placentae were obtained with informed consent after elective cesarean section delivery of noncomplicated term pregnancies. Insulin glargine, at a therapeutic concentration of 150 pmol/l (20 μU/ml) was added to the maternal circulation. Additional experiments were carried out at insulin glargine concentrations 1,000-fold higher than therapeutic levels (150, 225, and 300 nmol/l). A subsequent perfusion for which the maternal circuit remained open and insulin glargine was continuously infused at 150 pmol/l was completed for further confirmation of findings. The appearance of insulin glargine in the fetal circulation was analyzed by a chemiluminescence immunoassay. RESULTS: Results from perfusions carried out at therapeutic concentrations (150 pmol/l) of insulin glargine showed no detectable insulin glargine in the fetal circuit. After perfusion with very high insulin glargine concentrations of 150, 225, and 300 nmol/l, the rate of transfer remained low at 0.079 ± 0.01, 0.14, and 0.064 pmol · min−1 · g tissue−1, respectively. CONCLUSIONS: Insulin glargine, when used at therapeutic concentrations, is not likely to cross the placenta.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both of these long-acting insulin analogs, however, are widely used in pregnancy, with evidence of safety in this setting (33–37).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [36]
In the citing paper
“Nonetheless, glargine is unlikely to cross the placenta (36),”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin Degradation: Progress and Potential*
Duckworth, W. C., Bennett, R. G., & Hamel, F. G. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0349 · Cited by 871 · cited 2×
“However, at very high concentrations, it has been suggested that non– receptor-mediated processes, such as pinocytosis, may also be involved in insulin transport across cell membranes in other tissues (14).”
BackgroundLepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · cited 1×
“Experimental period In a closed-circuit experiment, insulin glargine was added at a therapeutic concentration of 150 pmol/l (20 U/ml) to the maternal circulations (n 4) (22).”
MethodKurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 2×
“Although the evidence to date is conflicting (16), one study demonstrated that glargine has a six- to eightfold increased affinity for the IGF-1 receptor in the osteosarcoma cell line Saos/B10 (15).”
BackgroundYki-Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 579
Managing preexisting diabetes for pregnancy
Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., et al. (2008) · Diabetes Care · doi:10.2337/dc08-9020 · Cited by 476
Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study
Jovanovic-Peterson, L., Peterson, C. M., Reed, G. F., Metzger, B. E., Mills, J. L., Knopp, R. H., & Aarons, J. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90637-7 · Cited by 411 · cited 1×
“Such insulins may be particularly useful in pregnancy because tight glycemic control during gestation decreases the risk of maternal and fetal complications (5–10) and attenuates their severity (9).”
BackgroundPreconception Care of Diabetes: Glycemic Control Prevents Congenital Anomalies
Kitzmiller, J. L. (1991) · JAMA · doi:10.1001/jama.1991.03460060063025 · Cited by 397
Reduced Hypoglycemia Risk With Insulin Glargine
Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., & Salzman, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.950 · Cited by 371
Maternal postprandial glucose levels and infant birth weight: The Diabetes in Early Pregnancy Study
Jovanovic‐Peterson, L., Peterson, C., Reed, G., Metzger, B., Mills, J., Knopp, R., & Aarons, J. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90499-u · Cited by 322
Plank, J., Bodenlenz, M., Sinner, F., Magnes, C., Görzer, E., Regittnig, W., Endahl, L. A., Draeger, E., Zdravkovic, M., & Pieber, T. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1107 · Cited by 271 · cited 1×
“These long-acting insulins have the advantage of a very long elimination half-life (24 h), avoiding a peak in insulin concentrations (1,2).”
Background
Research works printed but not linked: 1
- Ciaraldi, 2005, Effects of the rapid-acting insulin analogue insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and insulin-like growth factor-1, J Clin Endocrinol Metab, 86, 5838, 10.1210/jcem.86.12.8110 · doi:10.1210/jcem.86.12.8110 · Paper page
Cited by
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
Thompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Self-citation15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s014 · Cited by 265
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Coustan, D. R. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.203331 · Cited by 250
Egan, A. M., Dennedy, M. C., Al-Ramli, W., Heerey, A., Avalos, G., & Dunne, F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2684 · Cited by 125
Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis
Pollex, E., Moretti, M. E., Koren, G., & Feig, D. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p327 · Cited by 116
Self-citationDiabetes gestacional: um algoritmo de tratamento multidisciplinar
Weinert, L. S., Silveiro, S. P., Oppermann, M. L. D. R., Salazar, C. C., Simionato, B. M., Siebeneichler, A., & Reichelt, A. J. (2011) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302011000700002 · Cited by 147
“O estudo ex-vivo de placentas a termo, retiradas de gestações sem intercorrências, demonstrou ausência de transferência placentária da insulina glargina; entretanto, é necessária cautela ao extrapolar esses dados para gestações de primeiro trimestre e para gestantes diabéticas (35).”
Background15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 169
Lepercq, J., Lin, J., Hall, G. C., Wang, E., Dain, M.-P., Riddle, M. C., & Home, P. D. (2012) · Obstetrics and Gynecology International · doi:10.1155/2012/649070 · Cited by 95
Nguyen, D., Hsu Jean, W., Jahoor, F., & Sekhar Rajagopal, V (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2376 · Cited by 93
Safety of insulin analogs during pregnancy: a meta-analysis
Lv, S., Wang, J., & Xu, Y. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3692-3 · Cited by 88
“[35] demonstrated that glargine cannot cross the placenta to influence fetal growth.”
BackgroundMetformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
Brand, K. M. G., Saarelainen, L., Sõnajalg, J., Boutmy, E., Foch, C., Vääräsmäki, M., Morin-Papunen, L. C., Schlachter, J., CLUE Study Group, Hakkarainen, K. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002363 · Cited by 97
ADIPS 2020 guideline for pre‐existing diabetes and pregnancy
Rudland, V. L., Price, S., Hughes, R. C. E., Barrett, H. L., Lagstrom, J., Porter, C., Britten, F. L., Glastras, S. J., Fulcher, I., Wein, P., et al. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13265 · Cited by 87
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003126 · Cited by 73
Type 1 diabetes mellitus and pregnancy.
Vargas, R., Repke, J. T., & Ural, S. (2010) · PubMed · Cited by 102
Insulin during pregnancy, labour and delivery
de Valk, H. W., & Visser, G. H. A. (2010) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.002 · Cited by 72
Bruttomesso, D., Bonomo, M., Costa, S., Pos, M. D., Cianni, G. D., Pellicanò, F., Vitacolonna, E., Dodesini, A. R., Tonutti, L., Lapolla, A., et al. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.02.002 · Cited by 69
Negrato, C. A., Rafacho, A., Negrato, G., Teixeira, M. F., Araújo, C. A. R., Vieira, L., Silva, C. A., Date, S. K., Demarchi, A. C., & Gomes, M. B. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.015 · Cited by 55
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
King, A. B., & Poon (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s7301 · Cited by 62
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Goeden, N., & Bonnin, A. (2013) · Nature Protocols · doi:10.1038/nprot.2012.144 · Cited by 47
Mathiesen, E. R., Damm, P., Jovanovic, L., McCance, D. R., Thyregod, C., Jensen, A. B., & Hod, M. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1213 · Cited by 43
Contraception, and pregnancy in adolescents with type 1 diabetes: a review
Ethel Codner, D., Néstor Soto, I., & Merino, P. M. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00825.x · Cited by 41
Diabetes und Schwangerschaft: Update 2011
Kleinwechter, H. J. (2011) · Der Diabetologe · doi:10.1007/s11428-010-0672-x · Cited by 39
The metabolic and mitogenic properties of basal insulin analogues
Tennagels, N., & Ulrich, W. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.754474 · Cited by 41
Pregestational Diabetes in Pregnancy
Sugrue, R. P., & Zera, C. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2018.01.002 · Cited by 43
The transfer of pravastatin in the dually perfused human placenta
Żarek, J. A., DeGorter, M. K., Lubetsky, A., Kim, R. B., Laskin, C. A., Berger, H. M., & Koren, G. (2013) · Placenta · doi:10.1016/j.placenta.2013.05.002 · Cited by 38
Self-citationBismuth, É., Bouché, C., Caliman, C., Lepercq, J. A., Lubin, V., Rougé, D., Timsit, J., & Vambergue, A. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.02.010 · Cited by 35
Safety Considerations with Pharmacological Treatment of Gestational Diabetes Mellitus
Simmons, D. S. (2014) · Drug Safety · doi:10.1007/s40264-014-0253-9 · Cited by 34
“No RCTs of insulin glargine have taken place in GDM, but there have been a number of prospective, retrospective and case studies of insulin glargine use among women with GDM, and no evidence of harm has been shown [49, 50].”
BackgroundSafety of insulin analogues as compared with human insulin in pregnancy
Toledano, Y., Hadar, E., & Hod, M. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1182153 · Cited by 30
Therapeutic management of gestational diabetes
Jacqueminet, S., & Jannot-Lamotte, M.-F. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.11.016 · Cited by 34
Pharmacological Management of Gestational Diabetes Mellitus
Mukerji, G., & Feig, D. S. (2017) · Drugs · doi:10.1007/s40265-017-0807-0 · Cited by 40
Self-citationPharmacotherapy for hyperglycemia in pregnancy – The new insulins
Toledano, Y., Hadar, E., & Hod, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.035 · Cited by 32
Basal Insulin Treatment in Type 2 Diabetes
Hedrington, M. S., Pulliam, L., & Davis, S. N. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0062 · Cited by 28
Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes
Lepercq, J., Jacqueminet, S., Hieronimus, S., Timsit, J., & Grimaldi, A. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.11.008 · Cited by 24
Pharmacological treatment of gestational diabetes mellitus: point/counterpoint
Langer, O. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.024 · Cited by 27
Insulin analogues in pregnancy and specific congenital anomalies: a literature review
de Jong, J., Garne, E., Wender-Ożegowska, E., Morgan, M., den Berg, L. T. W. D. J., & Wang, H. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2730 · Cited by 27
Insulin analogues in the treatment of diabetes in pregnancy
Negrato, C. A., Montenegro, R. M., Kostrisch, L. M. V., Guedes, M. F. S., Mattar, R., & Gomes, M. B. (2012) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302012000700001 · Cited by 32
Contemporary management of gestational diabetes
Lee-Parritz, A. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834cd3c4 · Cited by 23
The impact of diabetes mellitus on the course and outcome of pregnancy during a 5-year follow-up
Mitrović, M., Stojic, S., Tešić, D., Popovic, D. S., Rankov, O., Tomić-Naglić, D., Novaković-Paro, J., Pejin, R., Bulatovic, S., Todorovic-Veljic, M., et al. (2014) · Vojnosanitetski pregled · doi:10.2298/vsp1410907m · Cited by 19
Pharmacotherapy for gestational diabetes
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1509955 · Cited by 19
“It does not cross the placenta at therapeutic doses [58].”
BackgroundMaternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy
Velasquez, J. C., Goeden, N., Herod, S. M., & Bonnin, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00287 · Cited by 14
Insulin Analogues in the Management of the Pregnancy Complicated by Diabetes Mellitus
Durnwald, C. P., & Landon, M. B. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0160-0 · Cited by 17
Ex vivo perfusion of the human placenta to investigate pregnancy pathologies
Zabel, R. R., Fávaro, R. R., Groten, T., Brownbill, P., & Jones, S. (2022) · Placenta · doi:10.1016/j.placenta.2022.10.006 · Cited by 19
Pharmacological Management of Gestational Diabetes Mellitus
Bergel, R., Hadar, E., Toledano, Y., & Hod, M. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0802-y · Cited by 18
Insulin Glargine Use During Pregnancy
Pantalone, K. M., Faiman, C., & Olansky, L. (2011) · Endocrine Practice · doi:10.4158/ep11083.ra · Cited by 13
Use of insulin glargine during pregnancy: A review
Jethwani, P., Saboo, B., Jethwani, L., Chawla, R., Maheshwari, A., Agarwal, S., & Jaggi, S. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.01.012 · Cited by 12
Prise en charge thérapeutique du diabète gestationnel
Jacqueminet, S., & Jannot-Lamotte, M.-F. (2010) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/s0368-2315(10)70051-x · Cited by 13
Glucose Targets and Insulin Choice in Pregnancy: What Has Changed in the Last Decade?
Bacon, S., & Feig, D. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1054-9 · Cited by 11
Self-citationMehri, K., Hamidian, G., Babri, S., Farajdokht, F., & Oskuye, Z. Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122517 · Cited by 9
Nalbandyan, M., Howley, M. M., Cunniff, C. M., Romitti, P. A., Browne, M. L., & Study, F. T. N. B. D. P. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61290 · Cited by 9
“Additionally, in vitro studies showed that therapeutic doses of insulin do not cross the human placenta (Boskovic et al., 2003; Pollex et al., 2010).”
BackgroundInsulin Therapy and Diabetic Pregnancy
Napoli, A. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001095 · Cited by 9
Monitoring and managing mothers with gestational diabetes mellitus: a nursing perspective
Berry, D. C., Johnson, Q. B., & Stuebe, A. (2015) · Nursing Research and Reviews · doi:10.2147/nrr.s64534 · Cited by 10
Placental Transfer of the Insulin Analog Glargine in the Ex Vivo Perfused Placental Cotyledon Model
Kovo, M., Golan, A., Wainstein, J., Matas, Z., Haroutounian, S., & Hoffman, A. (2011) · Endocrine Research · doi:10.3109/07435800.2010.534752 · Cited by 10
Saboo, B., Chandalia, H. B., Ghosh, S. K., Kesavadev, J., Kochar, I. S., Prasannakumar, K. M., Sarda, A., Bantwal, G., Mehrotra, R., & Rai, M. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230310150905 · Cited by 7
Cantacorps, L., Zhu, J., Yagoub, S., Coull, B. M., Falck, J. E., Chesters, R., Ritter, K., Serrano-Lope, M. A., Tscherepentschuk, K., Kasch, L.-S., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101860 · Cited by 6
Wang, J., Ji, X., Liu, T., & Zhao, N. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00925-7 · Cited by 8
Preconception Care for Women With Preexisting Type 2 Diabetes
Roman, M. A. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.1.10 · Cited by 7
Harreiter, J., & Kautzky‐Willer, A. (2016) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-016-0078-9 · Cited by 6
Use of Insulin Lispro Protamine Suspension in Pregnancy
Lapolla, A., Dalfrà, M. G., Romoli, E., Bonomo, M. A., & Moghetti, P. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0244-y · Cited by 8
Oral hypoglycemic agents: do the ends justify the means?
Langer, O. (2015) · Maternal Health Neonatology and Perinatology · doi:10.1186/s40748-015-0021-6 · Cited by 5
Controversies in Gestational Diabetes
Zera, C., & Seely, E. W. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.102 · Cited by 10
Prise en charge de la grossesse au cours du diabète de type 1
Bouché, C., Bismuth, É., Caliman, C., Lepercq, J. A., Lubin, V., Rougé, D., Timsit, J., & Vambergue, A. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70050-5 · Cited by 7
“[48] Pollex EK, Feig DS, Lubetsky A, et al.”
BackgroundGlättli, S. C., Elzinga, F. A., van der Bijl, W., Leuvenink, H. G. D., Prins, J. R., van Goor, H., Gordijn, S. J., Olinga, P., Touw, D. J., & Mian, P. (2024) · Placenta · doi:10.1016/j.placenta.2024.03.007 · Cited by 6
Drummond, R. F., Seif, K. E., Higgs, A. J., & Reece, E. A. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.08.088 · Cited by 3
Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Kwashie, E. K., Harley, Y., & Asiedu, B. N. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102247 · Cited by 7
“Insulin remains the preferred and safest pharmacological agent for glycemic management in pregnancy [224], as human insulin and certain analogues including aspart and detemir do not cross the placenta in clinically significant amounts [225].”
New Technologies for the Management of Pregestational Diabetes Mellitus
Lee-Parritz, A. (2012) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31824bb538 · Cited by 3
Weinert, L. S., Silveiro, S. P., Salazar, C. C., Marina, B. M., Siebeneichler, A., & Reichelt, A. J. (2011) · Americanae (AECID Library) · Cited by 3
Toledano, Y., Hadar, E., & Hod, M. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch56 · Cited by 5
Insulin therapy in diabetic kidney disease
Liu, Y., Zhao, C., Xiong, X., Yang, M., & Sun, L. (2021) · Diabetic Nephropathy · doi:10.2478/dine-2022-0006 · Cited by 2
Harreiter, J., & Kautzky‐Willer, A. (2011) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-011-0005-z · Cited by 2
Thompson, D. M., Berger, H. M., Feig, D. S., Gagnon, R. J., Kader, T., Keely, E., Kozak, S. E., Ryan, E. A., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.040 · Cited by 8
Self-citationShestakova, M. V., Mel'nichenko, G. A., Andreeva, E. N., Sukhareva, O. Y., Vorotnikova, S. Y., Ibragimova, L. I., Фархадовна, Б. Ф., Demidova, T. Y., Геннадьевна, Д. Е., Tiselko, A. V., et al. (2024) · Diabetes Mellitus · doi:10.14341/dm13161 · Cited by 2
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
Klimontov, V. V., & Мякина, Н. Е. (2014) · Diabetes Mellitus · doi:10.14341/dm2014499-107 · Cited by 1
Systematic Literature Review of Basal Bolus Insulin Analogue Therapy during Pregnancy
Henderson, C. E. (2015) · Obstetrics & Gynecology International Journal · doi:10.15406/ogij.2015.03.00079 · Cited by 3
Prise en charge de la grossesse au cours du diabète de type 1
Bouché, C., Bismuth, É., Caliman, C., Lepercq, J. A., Lubin, V., Rougé, D., Timsit, J., & Vambergue, A. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70201-2 · Cited by 5
Prepregnancy Management in the Clinical Approach to Diabetes Mellitus
Milionis, C., & Koukkou, E. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_10 · Cited by 1
Painter, R. C., Finken, M. J. J., & van Rijn, B. B. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.07.006 · Cited by 1
Consoli, A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_21 · Cited by 1
Evaluación de las distintas estrategias diagnósticas para diabetes gestacional
Rodríguez, I. (2012) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Medical Therapy in Pregnant Women with Diabetes
Lee, S. H., Ahn, J., & Kim, J. (2011) · Journal of Korean Diabetes · doi:10.4093/jkd.2011.12.4.201
Managing gestational diabetes: timing, selection and use of pharmacotherapy
Thung, S., & Landon, M. B. (2013) · Diabetes Management · doi:10.2217/dmt.13.48
Инсулин гларгин: фармакокинетические и фармакодинамические основы клинического эффекта
Klimontov, V. V., & Myakina, N. E. (2014) · doi:10.14341/dm6691-4788
Mitrovi, M., Popovi, D., Olivera, Pejin, R., & Bulatovi, S. (2014)
USO DE LOS ANÁLOGOS DE LA INSULINA DURANTE
Blasco, M. (2012)
Gortazar, L., Mañé, L., Chillarón, J. J., & Roux, J. A. F. (2017) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2017.02.009 · Cited by 2
Bergel, R., Hadar, E., Toledano, Y., & Hod, M. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_23-1 · Cited by 1
Management of gestational diabetes mellitus to optimize outcomes
Toledano, Y., Hadar, E., & Hod, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817921-5.00019-9
Diabetes in Pregnancy (Content last reviewed: 11th November 2020)
Soh, A. W.-E., Tan, L., & Yeo, G. S.-H. (2017)
Bergel, R., Hadar, E., Toledano, Y., & Hod, M. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_23
Current awareness: Pharmacoepidemiology and drug safety
(2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1853
Bergel, R., Hadar, E., Toledano, Y., & Hod, M. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_23-2
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1023
Bergel, R., Hadar, E., Toledano, Y., & Hod, M. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_23
Metadata
- Authors
- Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G.
- Affiliations
- University of Toronto (CA)
- Mount Sinai Hospital (CA)
- Hospital for Sick Children (CA)
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Corresponding author
- Koren, Gideon
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-10-06
- Volume
- 33
- Issue
- 1
- Pages
- 29-33
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2797979
- OpenAlex
- W2083261524
- Cited by
- 104
- References
- 26
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 10 · 2017: 3 · 2016: 4 · 2015: 7 · 2014: 5 · 2013: 10 · 2012: 7
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Hospital for Sick Children
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin glargine, placental transfer, pregnancy, insulin analogues, placental perfusion, diabetes in pregnancy, drug safety in pregnancy
- MeSH terms
- Insulin Glargine, Biological Transport, Female, Fetal Blood, Humans, Hypoglycemic Agents, Insulin, Maternal-Fetal Exchange, Perfusion, Placenta, Pregnancy, Insulin, Long-Acting, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.